Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Debt: 2019-2023

Historic Total Debt for Seres Therapeutics (MCRB) over the last 5 years, with Dec 2023 value amounting to $101.5 million.

  • Seres Therapeutics' Total Debt rose 1.74% to $102.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $102.5 million, marking a year-over-year increase of 1.74%. This contributed to the annual value of $101.5 million for FY2023, which is 100.72% up from last year.
  • Latest data reveals that Seres Therapeutics reported Total Debt of $101.5 million as of FY2023, which was up 100.72% from $50.6 million recorded in FY2022.
  • Seres Therapeutics' Total Debt's 5-year high stood at $101.5 million during FY2023, with a 5-year trough of $24.6 million in FY2020.
  • Moreover, its 3-year median value for Total Debt was $50.6 million (2022), whereas its average is $58.9 million.
  • As far as peak fluctuations go, Seres Therapeutics' Total Debt dropped by 0.04% in 2020, and later skyrocketed by 105.30% in 2022.
  • Yearly analysis of 5 years shows Seres Therapeutics' Total Debt stood at $24.6 million in 2019, then dropped by 0.04% to $24.6 million in 2020, then grew by 0.02% to $24.6 million in 2021, then surged by 105.30% to $50.6 million in 2022, then skyrocketed by 100.72% to $101.5 million in 2023.